ABOUT THIS STUDY
- Subjects with a physician documented history or diagnosis of persistent asthma for at least 6 months prior to Screening Visit 1.
Trough FEV1 must be 50-100% of predicted at Screening Visit 1.
Subjects who have been maintained on a stable dose of ICS over the previous month prior to screening.
- Subjects who have had a severe asthma exacerbation in the 2 months prior to screening.
Subjects meeting any of the criteria of 'very poorly controlled' according to the NIH EPR 3
Subjects with evidence or history of cardiovascular disease including angina, myocardial,
infarction, clinically significant cardiac arrhythmia (eg, atrial fibrillation, atrial
flutter,supraventricular tachycardia, ventricular tachycardia), systemic hypertension (SBP
> 160 mmHg or DBP >100mmHg), pulmonary hypertension or cerebrovascular disease (including
transient ischaemic attacks).
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.